TORONTO, CANADA / November 25, 2025 - Ripple Therapeutics Corporation, a clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants, is pleased to announce that, earlier this year, it entered into an evaluation program and licensing option agreement with an affiliate of Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better.
Ripple’s patented technology platform is based on a discovery that drugs can be chemically engineered into controlled release pharmaceuticals without the use of polymers. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly engineerable to tailor both drug dose and duration. Because there are no polymers, once the drug is gone, the implant is gone with no pro-inflammatory degradation products.
“We’ve known the team at Ripple for a number of years and have always been impressed with their technology platform,” commented Mayssa Attar, PhD, SVP Pharmaceutical and Consumer R&D Head. “We are pleased to be working with them on this innovative approach to sustained drug delivery which has the potential to improve upon the current standard of care for ophthalmic diseases.”
“We’re pleased to partner with Bausch + Lomb and look forward to working with them to develop sustained release implants that will benefit patients with extended duration and improved safety,” commented Tom Reeves, President & CEO, Ripple Therapeutics. “This is our third strategic collaboration transaction in the last 12 months, which we believe is a testament to the power of the Ripple technology platform and the breadth of its application.”
Under the terms of the agreement, Bausch + Lomb will fund the early-stage feasibility and preclinical evaluation of the target molecule and will have the option to license any formulations being evaluated under the program for additional financial consideration including milestones and royalties.
About Ripple Therapeutics
Ripple Therapeutics Corporation is a privately held clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants without the use of polymers. Our novel therapeutics provide better outcomes for patients, easier management of care for physicians and lower cost for payors. www.rippletherapeutics.com
Media Contact (Ripple)
Julie Fotheringham, V.P. Marketing, People & Culture, Ripple Therapeutics
M: 416-951-7988 E: jfotheringham@rippletherapeutics.com
